Here’s the latest I can share based on current publicly available information up to now.
- Merz USA has been active in the aesthetics and dermatology space, with historical moves such as acquisitions aimed at expanding its portfolio in energy-based devices and related technologies [cite ]. This reflects the company’s strategy to broaden its U.S. offerings in aesthetics and dermatology [cite ].
- In recent years there have been leadership and strategic discussions around Merz’s role in the U.S. market, including initiatives to grow presence in aesthetics, dermatology, and neurotoxin segments [cite ]. This aligns with Merz’s continued U.S. market ambitions [cite ].
- Publicly reported items from credible outlets indicate Merz engages in ongoing product and corporate development activity in the U.S., though the most current specific press releases may be behind corporate pages or not uniformly summarized in all outlets [cite ].
If you’d like, I can:
- Narrow to a specific aspect (e.g., product launches in the U.S., FDA-cleared devices, or corporate acquisitions) and pull the most recent, verifiable details.
- Check a few targeted sources (Merz USA press room, major industry outlets) for the latest exact dates and descriptions of announcements.